

S3 Table

Cytokine	SHAM	NX	NX LIRA	NX rel. to SHAM mean fold change	NX LIRA rel. to NX mean fold change
IFN γ	0.34 ± 0.06	0.85 ± 0.14	0.85 ± 0.08	2.50 ± 0.41 **	1.01 ± 0.09
IL-10	20.90 ± 2.83	43.76 ± 4.64	33.12 ± 3.17	2.09 ± 0.22 ***	0.76 ± 0.72
IL-5	2.45 ± 0.24	4.00 ± 0.41	5.82 ± 0.99	1.63 ± 0.17	1.45 ± 0.25
IL-6	23.28 ± 2.85	37.53 ± 13.03	54.02 ± 14.42	1.61 ± 0.56	1.44 ± 0.38
KC	153.80 ± 13.38	144.40 ± 11.48	165.70 ± 13.9	0.94 ± 0.07	1.15 ± 0.10
TNF α	24.36 ± 1.92	47.30 ± 3.55	44.07 ± 3.73	1.94 ± 0.15 ****	0.93 ± 0.08
MCP-1	983.10 ± 59.44	825.20 ± 53.01	968.40 ± 90.05	0.84 ± 0.05	1.17 ± 0.11
OPN	252.30 ± 18.53	396.00 ± 23.87	391.00 ± 14.51	1.57 ± 0.09 *	0.99 ± 0.04

Plasma cytokine levels measured at termination of Study 2 are shown as absolute values in column 1-3 (pg/mL, OPN: ng/mL) as well as fold change of uremic (NX) mice relative to control (SHAM) mice (column 4) and liraglutide treated uremic mice (NX LIRA) relative to uremic (NX) mice (column 5). Depicted values are mean±SEM. Statistical analysis was made by 1-way ANOVA followed by Sidak's multiple comparisons post-test. *p<0.05, **p<0.01, ***p<0.005, ****p<0.001. n=14-15 mice per group. OPN: Osteopontin, MCP-1: Monocyte Chemoattractant Protein-1, TNF α : Tumor necrosis factor alpha, KC: chemokine (C-X-C motif) ligand 1, IL-6: interleukin 6, IFN γ : interferon gamma, IL-10: interleukin 10, IL-5: interleukin 5.